SEARCH

SEARCH BY CITATION

References

  • 1
    Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994; 18: 501515.
  • 2
    Weingarten SR, Riedinger MS, Varis GR et al. Identification of low-risk hospitalized patients with pneumonia: implications of early conversion to oral antimicrobial therapy. Chest 1994; 105: 11091115.
  • 3
    Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 20802084.
  • 4
    Burack JH, Hahn JA, Saint-Maurice D, Jacobson MA. Microbiology of community-acquired bacterial pneumonia in persons with and at risk for human immunodeficiency virus type 1 infection. Arch Intern Med 1994; 154: 25892596.
  • 5
    Schaberg T, Lode H. Klinik und Diagnostik der ambulant erworbenen Pneumonien. Dtsch Med Wschr 1991; 116: 18771880.
  • 6
    Cassiere HA. Community-acquired pneumonia. Dis Mon 1998; 44: 616675.
  • 7
    Fang G, Fine DM, Orloff J et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990; 69: 307316.
  • 8
    The American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 17301754.
  • 9
    Ramirez J. Penicillin-resistant pneumococci: new-generation fluoroquinolones and lower respiratory tract infections. Hosp Med 1999; 35: 4349.
  • 10
    Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347382.
  • 11
    Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639651.
  • 12
    Hoellman DB, Lin G, Jacobs MR et al. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J Antimicrob Chemother 1999; 43: 645649.
  • 13
    Dubois J, St-Pierre C. An in vitro susceptibility study of gatifloxacin against Legionella spp. Diagn Microbiol Infect Dis 1999; 33: 261266.
  • 14
    Miyashita N, Niki Y, Kishimoto T. In vitro and in vivo activities of AM-1155 against Chlamydia spp. Antimicrob Agents Chemother 1997; 41: 13311334.
  • 15
    Jones RN, Pfaller MA, Doern GV et al. Antimicrobial activity of gatifloxacin, a newer 8-methoxy fluoroquinolone, tested against over 23 000 recent clinical isolates from the SENTRY Antimicrobial Surveillance Program, 1997 [abstract]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Washington DC: American Society for Microbiology, 1998; 225.
  • 16
    Jones RN, Biedenbach DJ, Erwin ME et al. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae. J Clin Microbiol 1999; 37: 19992002.
  • 17
    Jones RN, Johnson DM, Erwin ME et al. Antistreptococcal activity of gatifloxacin. Drugs 1999; 58(suppl 2): 164165.
  • 18
    Honeybourne D, Banerjee D, Andrews JM, Wise R. Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 2001; 48: 6366.
  • 19
    Siegel RE. The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia. Are we looking in the wrong place? Chest 1999; 116: 535538.
  • 20
    Beam TR, Gilbert DN, Kunin CM, eds. European guidelines for the clinical evaluation of anti-infective drug products. Munich: European Society of Clinical Microbiology and Infectious Diseases, 1993.
  • 21
    Farrington CP, Manning G. Test statistics and a sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference of non-unity relative risk. Stats Med 1990; 9: 14471454.
  • 22
    Hollander M, Woolfe DA. Nonparametric statistical methods. New York: Wiley, 1973.
  • 23
    File TM, Tan JS. Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia. Curr Opin Pulm Med 1997; 3: 8997.
  • 24
    Donowitz GR, Brandon ML, Salisbury JP et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomised, double-masked, comparative, multicenter study. Clin Ther 1997; 19: 936953.
  • 25
    Lode H, Garau J, Grassi C et al. Treatment of community-acquired pneumonia: a randomised comparison of sparfloxacin, amoxycillin–clavulanic acid and erythromycin. Eur Respir J 1995; 8: 19992007.
  • 26
    Portier H, May T, Proust A, the French Study Group. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996; 37(suppl A): 8391.
  • 27
    O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997; 40(suppl A): 7381.
  • 28
    File TM, Segreti J, Dunbar L et al. A multicenter, randomised study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 19651972.
  • 29
    Ramirez J, Nguyen T-H, Tellier G et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin. J Resp Dis 1999; 20(suppl 11): S40S48.
  • 30
    Dowell M, Mayer H, Anderson A et al. A randomised, double-blind, multicenter comparative study of gatifloxacin (GAT) 400 mg IV and PO vs ceftriaxone + erythromycin (CTX + ERY) in treatment of community-acquired pneumonia (CAP) requiring hospitalization [abstract 2241]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. Washington DC: American Society for Microbiology, 1999; 421.
  • 31
    Jones RN, Andes DR, Mandell LA et al. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002; 44: 93100.
  • 32
    Gotfried M, Quinn TC, Gothelf S et al. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study. Diagn Microbiol Infect Dis 2002; 44: 8591.
  • 33
    Nicholson SC, High KP, Gothelf S, Webb CD. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. Diagn Microbiol Infect Dis 2002; 44: 109116.
  • 34
    Jones RN, Pfaller M, Andes DR et al. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002; 44: 93100.
  • 35
    Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone. J Resp Dis 1999; 20(suppl 11): S70S76.
  • 36
    Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Safety 1995; 13: 343358.
  • 37
    Lietman PS. Fluoroquinolone toxicities. An update. Drugs 1995; 49: 159163.
  • 38
    Hayem G, Carbon C. A reappraisal of quinolone tolerability: the experience of their musculoskeletal effects. Drug Safety 1995; 13: 338342.
  • 39
    Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994; 18: 946950.
  • 40
    Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2: 378424.